These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 34439918)
1. Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes. Wang JL; Tsai YT; Lin CH; Cidem A; Staniczek T; Chang GR; Yen CC; Chen W; Chong KY; Chen CM Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439918 [TBL] [Abstract][Full Text] [Related]
2. Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer. Spence MM; Hui RL; Chang JT; Schottinger JE; Millares M; Rashid N J Manag Care Spec Pharm; 2017 Feb; 23(2):195-205. PubMed ID: 28125366 [TBL] [Abstract][Full Text] [Related]
3. [Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung Adenocarcinoma]. Li P; Li B; Shi Y; Zhang F; Shen S; Li X Zhongguo Fei Ai Za Zhi; 2019 Mar; 22(3):137-142. PubMed ID: 30909992 [TBL] [Abstract][Full Text] [Related]
4. Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma. Zhai X; Zheng Q; Yang L; Zhu Y; Li J; Liu Y; Wang Z Sci Rep; 2017 May; 7(1):1453. PubMed ID: 28469143 [TBL] [Abstract][Full Text] [Related]
5. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer. Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664 [TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514 [TBL] [Abstract][Full Text] [Related]
7. Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study. Jun N; Hanping W; Xiaoyan S; Yan X; Mengzhao W; Xiaotong Z; Li Z Thorac Cancer; 2020 Jul; 11(7):1869-1875. PubMed ID: 32406994 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet. Xiong Y; Zhao N; Zheng Y; Wang J; Wei F; Ren X Tumour Biol; 2017 Jun; 39(6):1010428317701639. PubMed ID: 28618954 [TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. Ricciuti B; Brambilla M; Cortellini A; De Giglio A; Ficorella C; Sidoni A; Bellezza G; Crinò L; Ludovini V; Baglivo S; Metro G; Chiari R Clin Transl Oncol; 2020 May; 22(5):708-716. PubMed ID: 31332704 [TBL] [Abstract][Full Text] [Related]
10. Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. Vernieri C; Signorelli D; Galli G; Ganzinelli M; Moro M; Fabbri A; Tamborini E; Marabese M; Caiola E; Broggini M; Hollander L; Gallucci R; Vandoni G; Gavazzi C; Triulzi T; Colombo MP; Rizzo AM; Corsetto PA; Pruneri G; de Braud F; Sozzi G; Torri V; Garassino MC Clin Lung Cancer; 2019 May; 20(3):e413-e417. PubMed ID: 30617039 [TBL] [Abstract][Full Text] [Related]
11. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial. Han B; Jin B; Chu T; Niu Y; Dong Y; Xu J; Gu A; Zhong H; Wang H; Zhang X; Shi C; Zhang Y; Zhang W; Lou Y; Zhu L; Pei J Int J Cancer; 2017 Sep; 141(6):1249-1256. PubMed ID: 28560853 [TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study. Wang Y; Chen J; Wu S; Hu C; Li X; Wang Y; Yang Y; Rajan N; Chen Y; Chen Y; Luo Z; Chen W BMC Cancer; 2014 Dec; 14():940. PubMed ID: 25495098 [TBL] [Abstract][Full Text] [Related]
13. Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. Shiraishi Y; Kishimoto J; Tanaka K; Sugawara S; Daga H; Hirano K; Azuma K; Hataji O; Hayashi H; Tachihara M; Mitsudomi T; Seto T; Nakagawa K; Yamamoto N; Okamoto I Clin Lung Cancer; 2020 Sep; 21(5):472-476. PubMed ID: 32381420 [TBL] [Abstract][Full Text] [Related]
14. [Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma]. He P; Wang Y; Yang S; Yu S; Wang Z; Li J; Wang B; Hao X; Wang H; Hu X; Zhang X; Shi Y Zhongguo Fei Ai Za Zhi; 2013 Oct; 16(10):529-34. PubMed ID: 24113006 [TBL] [Abstract][Full Text] [Related]
15. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements. Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546 [TBL] [Abstract][Full Text] [Related]
16. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Barlesi F; Scherpereel A; Gorbunova V; Gervais R; Vikström A; Chouaid C; Chella A; Kim JH; Ahn MJ; Reck M; Pazzola A; Kim HT; Aerts JG; Morando C; Loundou A; Groen HJ; Rittmeyer A Ann Oncol; 2014 May; 25(5):1044-52. PubMed ID: 24585722 [TBL] [Abstract][Full Text] [Related]
17. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer. Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170 [TBL] [Abstract][Full Text] [Related]
18. Clinical analysis of anlotinib as first-line treatment for elderly patients with advanced lung adenocarcinoma without driver gene mutations. Zhu J; Xie Q; Zhong A; Le Y Anticancer Drugs; 2022 Jan; 33(1):e584-e589. PubMed ID: 34387607 [TBL] [Abstract][Full Text] [Related]
19. Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma. Wang L; Tang C; Xu B; Yang L; Qu L; Li L; Li X; Wang W; Qin H; Gao H; He K; Liu X PLoS One; 2017; 12(6):e0179000. PubMed ID: 28594947 [TBL] [Abstract][Full Text] [Related]
20. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG). Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]